COVID-19-related findings in the 30 patients with COVID-19 and GBS
| Clinical findings (tested patients, n=30) | % (patients, n) |
| Nasopharyngeal swab positivity (30/30) | 83.4 (25) |
| Anti SARS-CoV-2 positivity (5/30) | 100 (5) |
| Interstitial pneumonia on chest X-ray (30/30) | 93.3 (28) |
| Interstitial pneumonia on chest CT (30/30) | 76.7 (23) |
| Symptoms (30/30) | Fever 79.3 (23) Cough 66,6 (20) Dyspnoea 56,6 (17) Dysgeusia 26.7 (8) Anosmia 20 (6) Gastrointestinal symptoms 13.3 (4) |
| Lymphopenia (30/30) | 66.6 (20) |
| Increased creatine kinase (22/30) | 13.6 (3) |
| PaO2 at hospitalisation (mean±SD) (30/30) | 63.05±15,60 mm Hg |
| Non-invasive ventilation (29/30) | 68.9 (20) |
| Invasive ventilation (29/30) | 17.2 (5) |
| SOFA score at hospitalisation (mean±SD) (30/30) | 4.17±4,01 |
| SOFA score at discharge (mean±SD) (30/30) | 2.33±1,81 |
| Interval from onset of COVID-19 symptoms and GBS symptoms (mean±SD) (30/30) | 24.2±11,6 days (median 23 days, IQR 16–35) |
GBS, Guillain-Barré syndrome; ICU, intensive care unit; SOFA, sequential organ failure assessment.